Request Trial
metamorworks / Shutterstock.com
17 July 2026NewsRegulation & IndustryMarisa Woutersen

Why is 2026 already a record year for M&A activity?

Blockbuster acquisitions are back, impacting the pharma industry at record pace. As billions flow into breakthrough science, LSIPR’s series explores what’s driving the surge, how today’s deals are done, and where IP makes the difference.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Regulation & Industry
Fran Salisbury: ‘There’s nothing quite like finding the missing piece’
5 August 2026   From advising pioneering startups to championing women in the profession, Fran Salisbury of Mewburn Ellis has spent her career making innovation count. Here, she reflects on the challenges, opportunities and motivations that continue to drive her.
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026   Dealmaking is at a record pace, but not every asset is in play. So what are the therapy areas commanding the fiercest bidding wars and what’s to come?
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026   With billions in revenue set to disappear as patents expire, pharmaceutical giants are racing to acquire their way out of trouble. But are there other drivers behind the surge—and how long can the momentum last?


Editor's picks

Where Big Pharma is betting big in the M&A boom
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026

Editor's picks

Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Biotech
Sanofi launches mRNA vaccine lawsuits at Moderna and Pfizer
15 July 2026
Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotech
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Regulation & Industry
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Regulation & Industry
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026

More features

Novo’s Dutch win sends ‘clear message’ to unapproved semaglutide sellers
Brown Rudnick lands largest lateral IP team hire in firm history
Fran Salisbury: ‘There’s nothing quite like finding the missing piece’
K&L Gates expands European practice with Munich team hire
Patent litigator joins Baker Botts in London as UPC grows in significance
Exclusive: Winston Taylor’s UK head of IP on pitching $1.75bn firm’s ‘humble, but lethal’ practice
Insulet asks Fed Circ to rehear $59.4m trade secret reversal
Arnold & Porter adds firepower to ITC practice with new partner hire